Statin use and the risk of Clostridium difficile in academic medical centres

Gut

Volumn 61, Issue 11, 2012, Pages 1538-1542

  Motzkus Feagans, ChristineAnne ^a   Pakyz, Amy ^a   Polk, Ronald ^a   Gambassi, Giovanni ^b   Lapane, Kate L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIBIOTIC AGENT; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; METRONIDAZOLE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VANCOMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; ICD-9-CM; INFECTION PREVENTION; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CONFIDENCE INTERVALS; CROSS INFECTION; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PYRROLES; REFERENCE VALUES; RISK ASSESSMENT; SEX DISTRIBUTION; SIMVASTATIN; UNITED STATES; YOUNG ADULT;

EID: 84867030101     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301378     Document Type: Article

References (45)

1. Janka J, O'Grady NP. Clostridium difficile infection: current perspectives. Curr Opin Crit Care 2009;15:149-53.
2. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
3. Mc-Master-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007;27:1029-39. (Pubitemid 46986690)
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile -related mortality rates, United States, 1999-2004. Emerg Inf Dis 2007;9:1417-19. (Pubitemid 47510317)
5. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;11:1219-27. (Pubitemid 47596558)
6. Wilcox MH, Cunniffe JG, Trundle C, et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23-30. (Pubitemid 26313206)
7. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S12-28.
8. Deneve C, Janoir C, Poilane I, et al. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009;33(Suppl 1):24-8.
9. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15. (Pubitemid 28438966)
10. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004;171:33-8. (Pubitemid 38925116)
11. McGuire T, Dobest P, Klepser D, et al. Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses 2009;73:1045-7.
12. Bjorkhem-Bergman L, Bergman P, Andersson J, et al. Statin treatment and mortality in bacterial infections: a systematic review and meta-analysis. PLoS One 2010;5:e10702.
13. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
14. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402. (Pubitemid 32001026)
15. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
16. Naggie S, Miller BA, Zuzak KB, et al . A caseecontrol study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011;124:276. e1-7.
17. Schmiedeskamp M, Harpe S, Polk R, et al . Use of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial Clostridium difficile infection. Infect Control Hosp Epidemiol 2009;30:1070-6.
18. Pakyz A, MacDougall C, Oinonen M, et al. Trends in antibacterial use in US academic health centers: 2002-2006. Arch Intern Med 2008;168:2254-60.
19. Dubberke ER, Reske KA, McDonald LC, et al. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006;10:1576-9. (Pubitemid 44570903)
20. Chandler RE, Hedberg K, Cieslak PR. Clostridium difficile-associated disease in Oregon: increasing incidence and hospital-level risk factors. Infect Control Hosp Epidemiol 2007;28:116-22. (Pubitemid 46374150)
21. Dubberke ER, Butler AM, Yokoe DS, et al . Multicenter study of surveillance for hospital-onset Clostridium difficile infection by use of ICD-9-CM diagnosis codes. Infect Control Hosp Epidemiol 2010;31:262-8.
22. Kaul P, Medvedev S, Hohmann SF, et al. Ionizing radiation exposure to patients admitted with acute myocardial infarction in the United States. Circulation 2010;22:2113-15.
23. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.
24. Dore DD, Lapane KL, Trivedi AN, et al. Association between statin use and risk for keratinocyte carcinoma in the Veterans Affairs Tropical Tretinoin Chemoprevention trial. Ann Intern Med 2009;150:9-18.
25. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010;48:196-202.
26. Sequist TD, Adams A, Zhang F, et al . Effect of quality improvement on racial disparities in diabetes care. Arch Intern Med 2006;166:675-81.
27. Segars LW, Lea AR. Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national cross-sectional study. Clin Ther 2008;30:2159-66.
28. Charlson ME, Pompei P, Ales KL, et al . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
29. Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999;52:1137-42. (Pubitemid 29535413)
30. Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for charlson comorbidity adjustment in medicare claims. Med Care 1999;37:1128-39.
31. Heard SR, O'Farrell S, Holland D, et al. The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J Infect Dis 1986;153:159-62. (Pubitemid 16212472)
32. Heeschen C, Hamm CW, Laufs U, et al; Platelet Receptor inhibition in Ischemic Syndrome management (PRISM) Investigators. Withdrawal of statins increases event rates in patient with acute coronary syndromes. Circulation 2002;105:1446-52. (Pubitemid 34263276)
33. Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol 2010;20:136-42.
34. Fonseca AC, Resende R, Oliveira CR, et al. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 2010;223:282-93.
35. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7. e1.
36. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008;71:118-22. (Pubitemid 351173264)
37. Janda S, Young A, Fitzgerald JM, et al. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010;25:656.e7-22.
38. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
39. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4. (Pubitemid 32440937)
40. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7. (Pubitemid 40349625)
41. Almog Y, Novack V, Eisinger M, et al . The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-8. (Pubitemid 46148524)
42. Coleman CI, Lucek DM, Hammond J, et al. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007;23:1783-90. (Pubitemid 47300376)
43. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006;32:160-4. (Pubitemid 43039392)
44. Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease [published correction appears in]. JAMA 2008;299:765.
45. Bell DS, O'Keefe JH. Rediscovering bile acid sequestrants. Diabetes Obes Metab 2009;11:1114-21.